華瀚健康產業(00587.HK)已成立復牌委員會處理事項續停牌
華瀚健康產業(00587.HK)公布,於6月11日成立復牌委員會,以處理有關實現復牌的所有事宜,包括但不限於與聯交所、證監會及其他監管機構就復牌條件、全權酌情處理牽涉的訴訟及法律程序、決定是否就復牌事宜及訴訟事宜而聘請及委任法律顧問、財務顧問、內部監控顧問及獨立第三方調查員、為實現復牌而就重組與第三方進行討論、磋商及決定、刊發有關復牌事宜及訴訟事宜的任何公告及通函。
而有關Cypress House Capital對公司提出之清盤程序,最大股東Bulls-Eye已與呈請人達成和解,並於5月27日提交同意傳訊令狀,請求撤銷經修訂呈請。
另外,非執行董事譚顯浩已提交辭職信,6月19日生效。公司續停牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.